The EndoPredict score is a vital tool for patients diagnosed with ER-positive, HER2-negative early-stage breast cancer. This calculator estimates the EPclin score, which combines molecular data with clinical factors to help determine the risk of distant recurrence.
What is the EndoPredict Score?
EndoPredict is a second-generation genomic test used to predict the likelihood of breast cancer spreading to other parts of the body (distant recurrence) within 10 years of diagnosis. Unlike earlier tests, EndoPredict provides information regarding both early (0–5 years) and late (5–10 years) recurrence risks.
How the Score is Calculated
The calculation is divided into two primary metrics:
- EP Score: This is the "molecular only" score. It analyzes the expression of 12 specific genes within the tumor tissue (8 protective genes, 3 proliferative genes, and 1 control gene).
- EPclin Score: This is the clinical-genomic score. It integrates the molecular EP score with the patient's tumor size and nodal status. Research consistently shows that the EPclin score is a more accurate predictor of risk than the molecular score alone.
Interpreting Your Results
The EPclin score typically ranges on a scale where a specific cutoff point distinguishes between "Low Risk" and "High Risk."
- Low Risk: Patients in this category have a low probability of distant recurrence. For many, this indicates that the benefits of chemotherapy may not outweigh the side effects, and hormone therapy alone may be sufficient.
- High Risk: Patients in this category have a higher probability of recurrence. In these cases, chemotherapy is often recommended in addition to hormone therapy to reduce the risk of the cancer returning.
Why Tumor Size and Nodal Status Matter
While the genetic makeup of a tumor tells us about its "behavior," the clinical factors tell us about its "progress." A small tumor that is molecularly aggressive might carry the same weight as a slightly larger tumor that is molecularly indolent. By combining these factors into the EPclin score, the EndoPredict score calculator provides a holistic view of the patient's prognosis.
Clinical Significance of EndoPredict
One of the unique advantages of the EndoPredict test is its ability to predict the risk of late recurrence. Many ER-positive breast cancers have a persistent risk of returning after the initial five-year treatment window. Knowing this risk helps oncologists decide if extended endocrine therapy (taking hormone blockers for 10 years instead of 5) is necessary.
If you are using this calculator, ensure you have your pathology report handy. The tumor size should be entered in millimeters (e.g., a 1.5 cm tumor is 15 mm), and your nodal status should be confirmed by your surgeon or pathologist.